Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery

  • Serna, Naroa|||0000-0001-5682-8198
  • Pallarès, Victor|||0000-0002-9851-0345
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Parladé, Eloi|||0000-0001-5750-550X
  • Rueda, Ariana|||0000-0001-7588-9279
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Sierra, Jorge|||0000-0002-7966-0356
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
Self-assembling non-immunoglobulin scaffold proteins are a promising class of nanoscale carriers for drug delivery and interesting alternatives to antibody-based carriers that are not sufficiently efficient in systemic administration. To exploit their potentialities in clinics, protein scaffolds need to be further tailored to confer appropriate targeting and to overcome their potential immunogenicity, short half-life in plasma and proteolytic degradation. We have here engineered three human scaffold proteins as drug carrier nanoparticles to target the cytokine receptor CXCR4, a tumoral cell surface marker of high clinical relevance. The capability of these scaffolds for the selective delivery of Monomethyl auristatin E has been comparatively evaluated in a disseminated mouse model of human, CXCR4+ acute myeloid leukemia. Monomethyl auristatin E is an ultra-potent anti-mitotic drug used against a range of hematological neoplasias, which because of its high toxicity is not currently administered as a free drug but as payload in antibody-drug conjugates. The protein nanoconjugates generated here offer a collective strength of simple manufacturing process, high proteolytic and structural stability and multivalent ligand receptor interactions that result in a highly efficient and selective delivery of the payload drug and in a potent anticancer effect. The approach shown here stresses this class of human scaffold proteins as promising alternatives to antibodies for targeted drug delivery in the rapidly evolving drug development landscape.
Dipòsit Digital de Documents de la UAB
Datos de investigación Set de datos (Dataset)

Raw data to support the manuscript "Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery"

  • Serna, Naroa|||0000-0001-5682-8198
  • Pallarès, Victor|||0000-0002-9851-0345
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Parladé, Eloi|||0000-0001-5750-550X
  • Rueda, Ariana|||0000-0001-7588-9279
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Sierra, Jorge|||0000-0002-7966-0356
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
Raw data of a set of experiments aimed to explore the suitability of different human proteins as scaffold for targeted nanocarriers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

An In Silico Methodology That Facilitates Decision Making in the Engineering of Nanoscale Protein Materials

  • Parladé, Eloi|||0000-0001-5750-550X
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Serna, Naroa|||0000-0001-5682-8198
  • Cano, Montserrat
  • Rodríguez-Mariscal, Manuel
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
Under the need for new functional and biocompatible materials for biomedical applications, protein engineering allows the design of assemblable polypeptides, which, as convenient building blocks of supramolecular complexes, can be produced in recombinant cells by simple and scalable methodologies. However, the stability of such materials is often overlooked or disregarded, becoming a potential bottleneck in the development and viability of novel products. In this context, we propose a design strategy based on in silico tools to detect instability areas in protein materials and to facilitate the decision making in the rational mutagenesis aimed to increase their stability and solubility. As a case study, we demonstrate the potential of this methodology to improve the stability of a humanized scaffold protein (a domain of the human nidogen), with the ability to oligomerize into regular nanoparticles usable to deliver payload drugs to tumor cells. Several nidogen mutants suggested by the method showed important and measurable improvements in their structural stability while retaining the functionalities and production yields of the original protein. Then, we propose the procedure developed here as a cost-effective routine tool in the design and optimization of multimeric protein materials prior to any experimental testing.